Compare FUTU & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUTU | CYTK |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 10.7B |
| IPO Year | 2018 | 2004 |
| Metric | FUTU | CYTK |
|---|---|---|
| Price | $96.62 | $85.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | ★ $217.75 | $89.26 |
| AVG Volume (30 Days) | 1.5M | ★ 2.4M |
| Earning Date | 05-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $27.96 | $7.37 |
| Revenue Next Year | $11.89 | $310.19 |
| P/E Ratio | $17.05 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $80.50 | $32.89 |
| 52 Week High | $202.53 | $88.31 |
| Indicator | FUTU | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 43.76 | 63.99 |
| Support Level | $88.78 | $59.07 |
| Resistance Level | $103.02 | $88.31 |
| Average True Range (ATR) | 4.74 | 2.85 |
| MACD | 1.30 | 0.17 |
| Stochastic Oscillator | 38.22 | 68.03 |
Futu Holdings Ltd is an online broker providing one-stop online investing services.. Through its proprietary digital platforms, Futubull and Moomoo, the Company provides a full range of investment services, including trade execution and clearing, margin financing and securities lending, and wealth management. The Group engages in online brokerage services and margin financing services. It generates its revenue in the form of brokerage commission and handling charge services, and interest income. Geographically, it operates in Hong Kong, which derives key revenue and it also has its presence in other countries.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.